The Full Story in Plain English
What the Study Found (In Plain English)
Why This Matters to You
An international journal of headache (2023), this phase iii randomized trial evaluating human clinical outcomes investigated: Following the CENTURION phase 3 randomized controlled trial's four-month gold-standard blind phase, this 12-month open-label extension collected data for up to one year about dose optimization, patterns of use, migraine-related disability, and quality of life during lasmiditan treatment. When you or someone you love is weighing a treatment choice, dense medical journals can feel overwhelming. Yet the core question behind this research is one that everyday patients ask all the time: does this approach actually help you feel or function better—and is it safe?
How the Study Worked
To find out, researchers writing in Cephalalgia : an international journal of headache conducted a phase iii randomized trial evaluating multiple clinical patient groups. Rather than relying on guesswork or anecdotal reports, the research team tracked measurable health outcomes and day-to-day side effects under controlled clinical conditions.
What the Study Found in Plain English
During this 12-month extension, lasmiditan was associated with a high rate of study completion, most attacks were treated with lasmiditan, and patients reported improvements in migraine-related disability and quality. Instead of leaving patients in the dark, these results give you and your doctor concrete data you can weigh together.
The Catch: What to Keep in Mind
Even strong medical studies have limits. Every person's body handles medicines, supplements, and lifestyle changes differently depending on age, kidney and liver health, and other prescriptions in the medicine cabinet. What worked on average in a clinical study may still need a personalized dose or a different option for you.
Bottom Line: Your Next Step
Bring this summary to your next doctor or pharmacist visit. Ask: "Based on my health history and current medications, does this research apply to me?" You can also click the formal study link below to inspect the original peer-reviewed paper directly.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Published in Cephalalgia : an international journal of headache (2023-04-15) • Study Design: Phase III Randomized Trial • Participants: Pooled Clinical Review • Biostatistical Rigor Score: 88/100. Primary Takeaway: During this 12-month extension, lasmiditan was associated with a high rate of study completion, most attacks were treated with lasmiditan, and patients reported improvements in migraine-related disability and quality.
Study Limitations & Caveats Before You Act
While this phase iii randomized trial scored 88/100 for research quality, clinical trials follow strict rules that may not match every patient's daily life. Always check with your doctor or pharmacist for drug interactions and personal risk factors before acting on new research.
Formal Peer-Reviewed Study Reference
“Long-term treatment with lasmiditan in patients with migraine: Results from the open-label extension of the CENTURION randomized trial”
Published in Cephalalgia : an international journal of headache (2023-04-15) • PMID/ID: 36950929